No Improvement of Patient or Graft Survival in Transplant Recipients Treated with Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Type 1 Receptor Blockers | Zendy

Gerhard Opelz | Zendy; Martin Zeier | Zendy; Gunter Laux | Zendy; Christian Morath | Zendy; Bernd Döhler | Zendy

Open Access

No Improvement of Patient or Graft Survival in Transplant Recipients Treated with Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Type 1 Receptor Blockers

Author(s) -

Gerhard Opelz,

Martin Zeier,

Gunter Laux,

Christian Morath,

Bernd Döhler

Publication year - 2006

Publication title -

journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.451

H-Index - 279

eISSN - 1533-3450

pISSN - 1046-6673

DOI - 10.1681/asn.2006050543

Subject(s) - medicine , angiotensin receptor blockers , angiotensin converting enzyme , kidney transplantation , kidney , kidney transplant , renin–angiotensin system , pharmacology , angiotensin ii , angiotensin receptor , transplantation , receptor , urology , blood pressure

It was reported recently that treatment of kidney transplant recipients with angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II type 1 receptor blockers (ARB) is associated with strikingly improved long-term graft and patient survival. This finding has important implications for future posttransplantation therapy recommendations. In an analysis of 17,209 kidney and 1744 heart transplant recipients, an association of treatment with ACEI/ARB with improved transplant outcome could not be confirmed. It is concluded that recommendations for a widespread use of ACEI/ARB treatment in transplant recipients are unwarranted.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research